ArticleJournal of hematopathology2026
From serologic uncertainty to diagnostic clarity in unusual adult T-cell leukemia/lymphoma via HBZ in situ hybridization.
Article in Journal of hematopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult T-cell leukemia/lymphoma (ATLL) is a rare T-cell neoplasm with geographic clustering, associated with human T-lymphotropic virus1 (HTLV-1), an oncoretrovirus. Clinical presentation is variable, and diagnosis can be challenging in atypical cases. We describe a 61-year-old man with aggressive CD4/CD8 double-positive T-cell lymphoma involving lymph nodes and bone marrow with circulating lymphoma cells. HTLV serology was positive, confirmed by western blot. However, due to the unusual presentation and absence of classic features such as hypercalcemia, skin lesions, or "flower" cells (circulating lymphoma cells with marked nuclear lobation), further confirmation was warranted. HTLV-1 bZIP factor (HBZ) in situ hybridization (ISH) was performed to confirm the diagnosis of ATLL. This case underscores the importance of including HTLV-1 serology in the initial workup of T-cell lymphomas and highlights the diagnostic value of HBZ ISH in ambiguous presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.